Regenerative Medical Technology (RMTG) Amortization of Deferred Charges (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Amortization of Deferred Charges of $729897.0 for Q1 2026, down 7.61% quarter-over-quarter from $790014.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Amortization of Deferred Charges (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $729897.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $729897.0; the TTM figure through Mar 2026 stood at $2.0 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, down 35.75% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $729897.0, down from $790014.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $1.0 million in Q2 2024, with the low at $4387.0 in Q4 2024.
- The 5-year median for Amortization of Deferred Charges is $729897.0 (2026), against an average of $598778.8.
- The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges sank 99.43% in 2024, then surged 17908.07% in 2025.
- Regenerative Medical Technology's Amortization of Deferred Charges stood at $436968.0 in 2022, then soared by 74.88% to $764156.0 in 2023, then tumbled by 99.43% to $4387.0 in 2024, then soared by 17908.07% to $790014.0 in 2025, then retreated by 7.61% to $729897.0 in 2026.
- Business Quant data shows RMTG's Amortization of Deferred Charges at $729897.0 in Q1 2026, $790014.0 in Q4 2025, and $518413.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 729,897.00 |
| Mar 31, 2026 | 729,897.00 |
| Dec 31, 2025 | 790,014.00 |
| Dec 31, 2025 | 790,014.00 |
| Sep 30, 2025 | 518,413.00 |
| Sep 30, 2025 | 518,413.00 |
| Dec 31, 2024 | 4,387.00 |
| Dec 31, 2024 | 4,387.00 |
| Sep 30, 2024 | 66,076.00 |
| Sep 30, 2024 | 66,076.00 |
| Jun 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 764,156.00 |
| Dec 31, 2023 | 764,156.00 |
| Sep 30, 2023 | 764,662.00 |
| Sep 30, 2023 | 764,662.00 |
| Jun 30, 2023 | 765,133.00 |
| Jun 30, 2023 | 765,133.00 |